Nov 5th, 2025
Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales
Novo Nordisk pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports.
